Table 2.
Summary of cardiac medication use, NYHA heart failure status, AHA heart failure stage, and LV diastolic function assessment.
| N | Beta Blocker | Ca++ Channel Blocker | ACE-I ARB | Diuretic | Spironolactone | Digoxin | |
|---|---|---|---|---|---|---|---|
| Cardiac Medication Classes | 25 | 54.2% (13) | 20.8% (5) | 33.3% (8) | 29.2% (7) | 20.8% (5) | 4.2% (1) |
| sub-group by LVEF | |||||||
| low (<50%) | 9 | 77.8% (7) | 11.1% (1) | 77.8% (7) | 44.4% (4) | 22.2% (2) | 11.1% (1) |
| preserved (>50%) | 16 | 37.5% (6) | 25% (4) | 6.3% (1) | 18.8% (3) | 18.8% (3) | 0% (0) |
| Normal | Grade I | Grade II | Grade III | Indeterminate | |||
| Transthoracic Echocardiography | 23 | 26.1% (6) | 39.1% (9) | 4.3% (1) | 13% (3) | 17.4% (4) | |
| 0 | 1 | 2 | 3 | 4 | |||
| NYHA Heart Failure Status | 30 | 14% (4) | 43% (13) | 26% (8) | 10 % (3) | 7% (2) | |
| A | B | C | D | ||||
| AHA Heart Failure Stage | 30 | 0% (0) | 10% (3) | 90% (27) | 0% (0) | ||
Summary of cardiac medication use, NYHA heart failure status, AHA heart failure stage, and LV diastolic function assessment. N reflects the number of patients for who the respective information was available.